Literature DB >> 1544011

Tacrine in Alzheimer's disease. Time course of changes in cognitive function and practice effects.

S Eagger1, N Morant, R Levy, B Sahakian.   

Abstract

This paper concerns certain questions which arose during the analysis of a trial showing positive effects of tacrine in Alzheimer's disease. Cognitive improvement occurred during the first two weeks, reached a maximum at one month and was maintained during the rest of the three-month treatment period. Rebound effects were not detected in any of the key outcome variables, but were suggested by one of the supporting cognitive tests and other measures. Practice effects occurred on tests which were repeated at short intervals or too frequently. The paper discusses the significance of these findings for the interpretation of other trials and for practical management.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1544011     DOI: 10.1192/bjp.160.1.36

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  7 in total

1.  Functional neuroimaging in Alzheimer's disease: how far should we go?

Authors:  R Kerwin
Journal:  Eur J Nucl Med       Date:  1994-10

2.  Do people with Alzheimer's disease improve with repeated testing? Unpacking the role of content and context in retest effects.

Authors:  Alden L Gross; Nadia Chu; Loretta Anderson; M Maria Glymour; Richard N Jones
Journal:  Age Ageing       Date:  2018-11-01       Impact factor: 10.668

3.  Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB.

Authors:  B J Sahakian; A M Owen; N J Morant; S A Eagger; S Boddington; L Crayton; H A Crockford; M Crooks; K Hill; R Levy
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 4.  Advances in the pharmacotherapy of Alzheimer's disease.

Authors:  J C Soares; S Gershon
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

Review 5.  Therapy for Alzheimer's disease. Symptomatic or neuroprotective?

Authors:  E Giacobini
Journal:  Mol Neurobiol       Date:  1994 Aug-Dec       Impact factor: 5.590

Review 6.  Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease.

Authors:  A J Wagstaff; D McTavish
Journal:  Drugs Aging       Date:  1994-06       Impact factor: 3.923

7.  Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials.

Authors:  Terry E Goldberg; Philip D Harvey; Keith A Wesnes; Peter J Snyder; Lon S Schneider
Journal:  Alzheimers Dement (Amst)       Date:  2015-03-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.